Diseases · Entity Annotation Prototype (beta)

4articles mentioning diseases

16disease mentions

1distinct diseases extracted

0%of mentions human-reviewed

Active filtersEntity: NASH ×

NASH

This disease is selected. Its supporting articles are shown below.

NASH4

Articles mentioning NASH

4 articles · page 1 of 1

Metabolic dysfunction associated steatotic liver disease: mechanisms, diagnosis, and management in adults

bmjmed · full text · 2026-03-31 · 10 matching annotations

92.8%

MASLD hepatocellular carcinoma

…, monitoring, and treatment needs to be established. Given that MASLD is a multisystem disease, assessing cost effectiveness should c…

IDDF2026-ABS-0534 Regional heterogeneity in liver cancer trends across high-income countries, 1990-2023: the emerging dominance of metabolic and alcohol-related disease

gutjnl · abstract · 2026-06-26 · 4 matching annotations

91.7%

Liver cancer hepatoblastoma LC NASH HCV-related LC HBV HCV NASH-related LC

…Background Liver cancer (LC) is among the most lethal and economically burdensome malig…

Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care

bmjdrc · full text · 2025-10-29 · 1 matching annotations

77.7%

type two diabetes mellitus T2DM end-stage renal disease chronic kidney disease type 2 diabetes mellitus diabetic neuropathy atherosclerotic cardiovascular disease A1C Diabetic retinopathy Obesity507+2 more

…ndard of care in improving glycemic control among patients with type two diabetes mellitus.While randomized trials provide robust evidence, there is incre…

P4 Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis

gutjnl · abstract · 2025-10-06 · 1 matching annotations

86.0%

MASH metabolic dysfunction-associated steatohepatitis NASH CSPH MASH cirrhosis portal hypertension Resmetirom

…trate clinical benefit in MAESTRO-NASH OUTCOMES, an ongoing 845 MASH cirrhosis patient clinical outcome study.…